Faster tests for brain infections can now get to patients sooner

US health regulators have made it easier to approve new tests for herpes simplex virus infections in the brain. This means patients can get diagnosed faster, which is critical for a disease that can cause severe brain damage or death.

For years, new diagnostic tests for serious conditions faced a slow approval process, even when they offered clear benefits. This change means that a specific type of test, a nucleic acid-based assay, can now get to market with less regulatory burden. It sets a precedent for how regulators might handle other critical diagnostic tools in the future, prioritizing patient access when safety and effectiveness are clear.